UK Employers Face New Duty-of-Care Guidance for Medical Cannabis Patients

Legal Framework Anchors Employer Obligations

UK employers owe medical cannabis patients the same duty of care required under the Equality Act 2010 for employees with disabilities, according to the new guidance. The framework clarifies that employees holding prescriptions issued under the Human Medicines Regulations 2012 qualify for workplace protections if their underlying condition meets the statutory definition of disability. The Equality Act defines disability as a physical or mental impairment with substantial, long-term adverse effects on the ability to carry out normal day-to-day activities.

Employers must make reasonable adjustments for medical cannabis patients. These include flexible scheduling for dosing, modified break policies, and exemptions from blanket drug-testing protocols that don't account for lawful prescription use. Failure to accommodate can trigger claims under sections 20 and 21 of the Equality Act, which mandate reasonable adjustments and prohibit discrimination arising from disability.

Employers retain the right to enforce safety-critical standards. Workers in roles governed by the Transport and Works Act 1992 or the Railways and Other Guided Transport Systems (Safety) Regulations 2006 may face restrictions if impairment is demonstrated, but blanket bans based solely on prescription status are unlawful.

Prescription Cannabis Use Surges 340 Percent Since 2023

The number of UK residents holding valid medical cannabis prescriptions climbed from approximately 23,000 in January 2023 to more than 101,000 by August 2026, according to data from the Medical Cannabis Clinicians Society. The surge follows expanded access to specialist prescriptions for chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea under National Health Service and private-clinic pathways.

Private clinics now account for 89 percent of prescriptions. The average patient age dropped from 52 to 41 years between 2024 and 2026. This shift has increased the likelihood that employers in sectors including retail, logistics, and professional services will encounter medical cannabis users among their workforce. The guidance was developed in response to a 270 percent rise in employment tribunal claims related to medical cannabis accommodation between 2024 and mid-2026.

Safety-Critical Roles Require Case-by-Case Assessment

Employers in safety-critical industries must conduct individualized assessments rather than impose categorical exclusions, the guidance states. Roles covered by the Civil Aviation Authority, the Office of Rail and Road, or the Health and Safety Executive's guidelines on drug and alcohol misuse require employers to assess actual impairment risk, not mere prescription status.

The framework recommends that employers consult occupational health professionals to evaluate whether a patient's dosing schedule, cannabinoid profile, or administration method poses a measurable safety risk. Employees using cannabidiol-dominant formulations with tetrahydrocannabinol content below 0.2 percent typically present lower impairment risk than those using high-THC oils for pain management. Employers must document the basis for any restriction and offer alternative roles where feasible.

The guidance cites the 2022 Employment Appeal Tribunal decision in Harrison v. Northern Rail Ltd., which held that an employer's refusal to consider individual circumstances when applying a drug policy constituted indirect discrimination. That precedent now extends to medical cannabis cases.

Drug-Testing Policies Must Distinguish Lawful Use

Blanket drug-testing policies that treat medical cannabis patients identically to recreational users violate the Equality Act, according to the guidance. Employers may conduct testing for safety-critical roles but must differentiate between lawful prescription use and unlawful possession. Testing protocols should measure impairment at the time of work, not metabolite presence that can persist for weeks after dosing.

Oral-fluid or performance-based testing is preferable to urinalysis, which detects inactive THC metabolites long after psychoactive effects have ceased. Employers who terminate employees based solely on positive urine tests without investigating prescription status face heightened liability for unfair dismissal and discrimination claims.

The framework also advises employers to update drug and alcohol policies to include explicit carve-outs for employees with valid prescriptions, provided they notify human resources and occupational health teams in advance. Confidentiality protections under the Data Protection Act 2018 apply to all medical disclosures.

Accommodation Requests Trigger Interactive Process

Employees who disclose medical cannabis use trigger a mandatory interactive process under the duty to make reasonable adjustments, the guidance states. Employers must engage in good-faith dialogue to identify accommodations that balance patient needs with operational requirements. Reasonable adjustments may include modified shift patterns to avoid peak cannabinoid effects, temporary reassignment during titration periods, or exemptions from random drug testing.

Refusing to engage carries risk. Employers who impose unilateral restrictions without consultation face tribunal findings of failure to make reasonable adjustments under section 20 of the Equality Act. Tribunals have awarded compensation ranging from £8,000 to £42,000 in recent medical cannabis accommodation cases, with amounts rising when employers demonstrate bad faith or procedural failures.

Employers aren't required to accommodate requests that impose undue hardship, defined as significant difficulty or expense relative to the employer's size and resources. But the threshold for undue hardship is high, and employers must provide evidence that no alternative accommodation exists.

What Employers Should Do Now

Employers should audit drug and alcohol policies, train human resources staff on medical cannabis obligations, and establish clear procedures for accommodation requests, according to the guidance. Policy updates should specify that employees with valid prescriptions won't face automatic adverse action and that testing protocols will account for lawful use.

Consulting employment law solicitors ensures compliance with the Equality Act, the Human Medicines Regulations, and sector-specific safety standards. Employers in safety-critical industries should engage occupational health physicians to develop impairment-assessment protocols tailored to cannabinoid pharmacology. For a full overview of workplace protections across jurisdictions, see the CannIntel topic hub on medical cannabis workplace rights at /topics/medical-cannabis-workplace-rights.

The next regulatory milestone is the anticipated publication of Health and Safety Executive guidance on cannabis impairment testing, expected in the first quarter of 2027. That guidance will address employer obligations under the Health and Safety at Work Act 1974 and provide technical standards for performance-based impairment assessment.